Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TE Connectivity plcTEL · Entity 3004 | Director | November 13, 2025 | November 14, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TE Connectivity plc
Report date November 13, 2025 · Filed November 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 7,123 |
Ending reported balance
After 2025-11-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-11-13 · Grant · Acquired 838 · Balance 7,526 F1: Grant of shares by the Issuer under directors' compensation program and Issuer's stock and incentive plan. Row 2 · 2025-11-13 · Tax withholding · Disposed 403 · Balance 7,123 |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of shares by the Issuer under directors' compensation program and Issuer's stock and incentive plan.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Keenova Therapeutics plc
Report date June 16, 2022 · Filed June 21, 2022
Section 16 reporting ended · disclosed 2022-06-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.73 · Expires 2022-12-02 | Direct | 0 |
Reported balance
After 2022-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-16 · Disposition to issuer · Disposed 38,875 · Balance 0 F1: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. |
| Employee Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.00 · Expires 2023-06-30 | Direct | 0 |
Reported balance
After 2022-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-16 · Disposition to issuer · Disposed 234,437 · Balance 0 F1: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. |
| Employee Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.35 · Expires 2024-01-02 | Direct | 0 |
Reported balance
After 2022-06-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-06-16 · Disposition to issuer · Disposed 63,542 · Balance 0 F1: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. |
| Employee Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $96.96 · Expires 2025-01-02 | Direct | 0 |
Reported balance
After 2022-06-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-06-16 · Disposition to issuer · Disposed 108,014 · Balance 0 F1: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. |
| Employee Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.61 · Expires 2026-01-04 | Direct | 0 |
Reported balance
After 2022-06-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-06-16 · Disposition to issuer · Disposed 175,528 · Balance 0 F1: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. |
| Employee Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.73 · Expires 2027-01-03 | Direct | 0 |
Reported balance
After 2022-06-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-06-16 · Disposition to issuer · Disposed 249,785 · Balance 0 F1: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. |
| Employee Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.80 · Expires 2028-04-02 | Direct | 0 |
Reported balance
After 2022-06-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-06-16 · Disposition to issuer · Disposed 946,003 · Balance 0 F1: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. |
| Employee Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.26 · Expires 2029-04-01 | Direct | 0 |
Reported balance
After 2022-06-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-06-16 · Disposition to issuer · Disposed 514,002 · Balance 0 F1: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code.
F2: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy.
F3: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 13, 2025 Filed Nov 14, 2025 18:41 UTC | TE Connectivity plc TEL · Entity 3004 | Tax withholdingCommon Shares | 403 | $236.28 | $95,220.84 |
DisclosureSEC source: 0001225208-25-009159 · doc4.xml · nonDerivative · entry 2 Trudeau Mark · CIK 0001540412 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,123 Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 18:41 UTC | TE Connectivity plc TEL · Entity 3004 | GrantCommon Shares | 838 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-009159 · doc4.xml · nonDerivative · entry 1 Trudeau Mark · CIK 0001540412 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,526 F1 · shares: Grant of shares by the Issuer under directors' compensation program and Issuer's stock and incentive plan. Read SEC document |
| November 14, 2024 Filed Nov 15, 2024 21:16 UTC | TE Connectivity plc TEL · Entity 3004 | Tax withholdingCommon Shares | 556 | $153.25 | $85,207.00 |
DisclosureSEC source: 0001225208-24-009990 · doc4.xml · nonDerivative · entry 2 Trudeau Mark · CIK 0001540412 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,688 Read SEC document |
| November 14, 2024 Filed Nov 15, 2024 21:16 UTC | TE Connectivity plc TEL · Entity 3004 | GrantCommon Shares | 1,327 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-009990 · doc4.xml · nonDerivative · entry 1 Trudeau Mark · CIK 0001540412 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,244 F1 · shares: Grant of shares by the Issuer under directors' compensation program and Issuer's stock and incentive plan. Read SEC document |
| April 29, 2024 Filed Apr 29, 2024 21:17 UTC | TE Connectivity plc TEL · Entity 3004 | SaleCommon Shares | 7,044 | $141.49 | $996,655.56 |
DisclosureSEC source: 0001225208-24-005341 · doc4.xml · nonDerivative · entry 1 Trudeau Mark · CIK 0001540412 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,917 F1 · price: The reported price is the weighted average price for the transactions on April 29, 2024. The range of prices for the transactions is from $141.46 to $141.53 per share. Information regarding the number of shares sold at each separate price will be provided upon request to the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 20:59 UTC | TE Connectivity plc TEL · Entity 3004 | Tax withholdingCommon Shares | 382 | $135.50 | $51,761.00 |
DisclosureSEC source: 0001225208-23-011104 · doc4.xml · nonDerivative · entry 2 Trudeau Mark · CIK 0001540412 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,961 Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 20:59 UTC | TE Connectivity plc TEL · Entity 3004 | GrantCommon Shares | 1,525 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-011104 · doc4.xml · nonDerivative · entry 1 Trudeau Mark · CIK 0001540412 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,343 F1 · price: Grant of shares by the Issuer under directors' compensation program and Issuer's stock and incentive plan. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 13:22 UTC | TE Connectivity plc TEL · Entity 3004 | Tax withholdingCommon Shares | 428 | $124.52 | $53,294.56 |
DisclosureSEC source: 0001225208-22-011704 · doc4.xml · nonDerivative · entry 2 Trudeau Mark · CIK 0001540412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,818 Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 13:22 UTC | TE Connectivity plc TEL · Entity 3004 | GrantCommon Shares | 1,709 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-011704 · doc4.xml · nonDerivative · entry 1 Trudeau Mark · CIK 0001540412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,246 F1 · price: Grant of shares by the Issuer under directors' compensation program and Issuer's stock and incentive plan. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 18:16 UTC | Keenova Therapeutics plc MNKPF · Entity 28960 | Disposition to issuerEmployee Share Options (Right to Buy) · Derivative | 514,002 | $0.00 Strike: $22.26 | $0.00 |
DisclosureSEC source: 0000899243-22-023438 · doc4.xml · derivative · entry 8 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary shares · 514,002 shares Expires 2029-04-01 F1 · kind: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2 · kind: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3 · kind: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 18:16 UTC | Keenova Therapeutics plc MNKPF · Entity 28960 | Disposition to issuerEmployee Share Options (Right to Buy) · Derivative | 946,003 | $0.00 Strike: $13.80 | $0.00 |
DisclosureSEC source: 0000899243-22-023438 · doc4.xml · derivative · entry 7 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary shares · 946,003 shares Expires 2028-04-02 F1 · kind: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2 · kind: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3 · kind: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 18:16 UTC | Keenova Therapeutics plc MNKPF · Entity 28960 | Disposition to issuerEmployee Share Options (Right to Buy) · Derivative | 249,785 | $0.00 Strike: $51.73 | $0.00 |
DisclosureSEC source: 0000899243-22-023438 · doc4.xml · derivative · entry 6 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary shares · 249,785 shares Expires 2027-01-03 F1 · kind: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2 · kind: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3 · kind: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 18:16 UTC | Keenova Therapeutics plc MNKPF · Entity 28960 | Disposition to issuerEmployee Share Options (Right to Buy) · Derivative | 175,528 | $0.00 Strike: $72.61 | $0.00 |
DisclosureSEC source: 0000899243-22-023438 · doc4.xml · derivative · entry 5 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary shares · 175,528 shares Expires 2026-01-04 F1 · kind: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2 · kind: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3 · kind: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 18:16 UTC | Keenova Therapeutics plc MNKPF · Entity 28960 | Disposition to issuerEmployee Share Options (Right to Buy) · Derivative | 108,014 | $0.00 Strike: $96.96 | $0.00 |
DisclosureSEC source: 0000899243-22-023438 · doc4.xml · derivative · entry 4 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary shares · 108,014 shares Expires 2025-01-02 F1 · kind: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2 · kind: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3 · kind: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 18:16 UTC | Keenova Therapeutics plc MNKPF · Entity 28960 | Disposition to issuerEmployee Share Options (Right to Buy) · Derivative | 63,542 | $0.00 Strike: $51.35 | $0.00 |
DisclosureSEC source: 0000899243-22-023438 · doc4.xml · derivative · entry 3 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary shares · 63,542 shares Expires 2024-01-02 F1 · kind: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2 · kind: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3 · kind: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 18:16 UTC | Keenova Therapeutics plc MNKPF · Entity 28960 | Disposition to issuerEmployee Share Options (Right to Buy) · Derivative | 234,437 | $0.00 Strike: $44.00 | $0.00 |
DisclosureSEC source: 0000899243-22-023438 · doc4.xml · derivative · entry 2 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary shares · 234,437 shares Expires 2023-06-30 F1 · kind: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2 · kind: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3 · kind: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 18:16 UTC | Keenova Therapeutics plc MNKPF · Entity 28960 | Disposition to issuerEmployee Share Options (Right to Buy) · Derivative | 38,875 | $0.00 Strike: $41.73 | $0.00 |
DisclosureSEC source: 0000899243-22-023438 · doc4.xml · derivative · entry 1 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary shares · 38,875 shares Expires 2022-12-02 F1 · kind: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2 · kind: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3 · kind: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. Read SEC document |
| December 09, 2021 Filed Dec 13, 2021 21:40 UTC | TE Connectivity plc TEL · Entity 3004 | Tax withholdingCommon Shares | 312 | $157.14 | $49,027.68 |
DisclosureSEC source: 0001225208-21-014842 · doc4.xml · nonDerivative · entry 2 Trudeau Mark · CIK 0001540412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,537 Read SEC document |
| December 09, 2021 Filed Dec 13, 2021 21:40 UTC | TE Connectivity plc TEL · Entity 3004 | GrantCommon Shares | 1,247 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-014842 · doc4.xml · nonDerivative · entry 1 Trudeau Mark · CIK 0001540412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,849 F1 · price: Grant of shares by the Issuer under directors' compensation program and Issuer's stock and incentive plan. Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 16:15 UTC | Keenova Therapeutics plc MNKKQ · Entity 28960 | SaleOrdinary Shares | 217,072 | $0.13 | $27,394.49 |
DisclosureSEC source: 0000950138-20-000469 · edgar.xml · nonDerivative · entry 1 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,312 F1 · price: The price represents a weighted average. The shares were sold in multiple transactions at prices ranging from $0.125 to $0.1286, inclusive. Mr. Trudeau will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 21:22 UTC | TE Connectivity plc TEL · Entity 3004 | Tax withholdingCommon Shares | 447 | $105.86 | $47,319.42 |
DisclosureSEC source: 0001225208-20-013454 · doc4.xml · nonDerivative · entry 2 Trudeau Mark · CIK 0001540412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,602 Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 21:22 UTC | TE Connectivity plc TEL · Entity 3004 | GrantCommon Shares | 1,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-013454 · doc4.xml · nonDerivative · entry 1 Trudeau Mark · CIK 0001540412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,049 F1 · price: Grant of shares by the Issuer under directors' compensation program and Issuer's stock and incentive plan. Read SEC document |
| January 04, 2020 Filed Jan 7, 2020 20:20 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 1,843 | $3.26 | $6,008.18 |
DisclosureSEC source: 0000950138-20-000021 · edgar.xml · nonDerivative · entry 2 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,384 F1 · balance_after: Includes 376 shares acquired under the Mallinckrodt employee stock purchase plan. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 20:20 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 3,403 | $3.36 | $11,434.08 |
DisclosureSEC source: 0000950138-20-000021 · edgar.xml · nonDerivative · entry 1 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,227 F1 · balance_after: Includes 376 shares acquired under the Mallinckrodt employee stock purchase plan. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 20:48 UTC | TE Connectivity plc TEL · Entity 3004 | Tax withholdingCommon Shares | 497 | $93.63 | $46,534.11 |
DisclosureSEC source: 0001225208-19-014451 · doc4.xml · nonDerivative · entry 2 Trudeau Mark · CIK 0001540412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,264 Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 20:48 UTC | TE Connectivity plc TEL · Entity 3004 | GrantCommon Shares | 1,988 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-014451 · doc4.xml · nonDerivative · entry 1 Trudeau Mark · CIK 0001540412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,761 F1 · price: Grant of shares by the Issuer under directors' compensation program and Issuer's stock and incentive plan. Read SEC document |
| May 30, 2019 Filed May 31, 2019 07:05 UTC | Keenova Therapeutics plc MNK · Entity 28960 | PurchaseOrdinary Shares | 2,000 | $9.26 | $18,528.00 |
DisclosureSEC source: 0000950138-19-000329 · edgar.xml · nonDerivative · entry 1 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,254 F1 · price: The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $9.24 to $9.28, inclusive. Mr. Trudeau will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range. Read SEC document |
| May 09, 2019 Filed May 10, 2019 08:06 UTC | Keenova Therapeutics plc MNK · Entity 28960 | PurchaseOrdinary Shares | 1,000 | $16.33 | $16,325.00 |
DisclosureSEC source: 0000950138-19-000298 · edgar.xml · nonDerivative · entry 1 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,254 F1 · price: The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $16.31 to $16.34, inclusive. Mr. Trudeau will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range. F2 · balance_after: Includes 1,002 shares acquired on March 31, 2019 under the Mallinckrodt employee stock purchase plan. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 17:36 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantEmployee Share Options (Right to Buy) · Derivative | 514,002 | $0.00 Strike: $22.26 | $0.00 |
DisclosureSEC source: 0000950138-19-000217 · edgar.xml · derivative · entry 1 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 514,002 Underlying: Ordinary Shares · 514,002 shares Expires 2029-04-01 F1 · derivative.exercise_date: The options vest in four equal annual installments beginning April 1, 2020. Read SEC document |
| March 05, 2019 Filed Mar 6, 2019 08:18 UTC | Keenova Therapeutics plc MNK · Entity 28960 | PurchaseOrdinary Shares | 1,000 | $22.65 | $22,650.00 |
DisclosureSEC source: 0000950138-19-000127 · edgar.xml · nonDerivative · entry 1 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,252 Read SEC document |
| January 04, 2019 Filed Jan 7, 2019 17:52 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 3,184 | $17.21 | $54,796.64 |
DisclosureSEC source: 0000950138-19-000019 · edgar.xml · nonDerivative · entry 2 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,252 Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 17:52 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 3,773 | $16.14 | $60,896.22 |
DisclosureSEC source: 0000950138-19-000019 · edgar.xml · nonDerivative · entry 1 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,436 Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 17:54 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 1,045 | $16.59 | $17,336.55 |
DisclosureSEC source: 0000950138-19-000007 · edgar.xml · nonDerivative · entry 1 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,209 Read SEC document |
| December 10, 2018 Filed Dec 11, 2018 08:30 UTC | Keenova Therapeutics plc MNK · Entity 28960 | PurchaseOrdinary Shares | 1,000 | $20.18 | $20,180.10 |
DisclosureSEC source: 0000950138-18-000653 · edgar.xml · nonDerivative · entry 1 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,254 F1 · price: The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $20.15 to $20.19, inclusive. Mr. Trudeau will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range. F2 · balance_after: Includes 1 share acquired on June 30, 2018 under the Mallinckrodt employee stock purchase plan. Read SEC document |
| November 12, 2018 Filed Nov 13, 2018 21:00 UTC | TE Connectivity plc TEL · Entity 3004 | Tax withholdingCommon Shares | 596 | $76.66 | $45,689.36 |
DisclosureSEC source: 0001225208-18-015454 · doc4.xml · nonDerivative · entry 2 Trudeau Mark · CIK 0001540412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,773 Read SEC document |
| November 12, 2018 Filed Nov 13, 2018 21:00 UTC | TE Connectivity plc TEL · Entity 3004 | GrantCommon Shares | 2,381 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-015454 · doc4.xml · nonDerivative · entry 1 Trudeau Mark · CIK 0001540412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,369 F1 · price: Grant of shares by the Issuer under directors' compensation program and Issuer's stock and incentive plan. Read SEC document |
| July 01, 2018 Filed Jul 3, 2018 16:33 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 34,708 | $18.66 | $647,651.28 |
DisclosureSEC source: 0000950138-18-000465 · edgar.xml · nonDerivative · entry 1 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,253 Read SEC document |
| May 16, 2018 Filed May 18, 2018 16:46 UTC | Keenova Therapeutics plc MNK · Entity 28960 | PurchaseOrdinary Shares | 3,000 | $15.54 | $46,614.60 |
DisclosureSEC source: 0000950138-18-000427 · edgar.xml · nonDerivative · entry 1 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,961 F1 · price: The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $15.525 to $15.55, inclusive. Mr. Trudeau will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range. F2 · balance_after: Includes 1,062 shares acquired on March 31, 2018 under the Mallinckrodt employee stock purchase plan. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 17:53 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantEmployee Share Options (Right to Buy) · Derivative | 946,003 | $0.00 Strike: $13.80 | $0.00 |
DisclosureSEC source: 0000950138-18-000301 · edgar.xml · derivative · entry 1 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 946,003 Underlying: Ordinary Shares · 946,003 shares Expires 2028-04-02 F1 · derivative.exercise_date: The options vest in four equal annual installments beginning April 2, 2019. Read SEC document |
| January 04, 2018 Filed Jan 5, 2018 19:44 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 2,644 | $23.40 | $61,869.60 |
DisclosureSEC source: 0000950138-18-000055 · edgar.xml · nonDerivative · entry 2 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,899 Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 19:44 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 4,370 | $23.51 | $102,738.70 |
DisclosureSEC source: 0000950138-18-000055 · edgar.xml · nonDerivative · entry 1 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,543 Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 19:08 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 6,511 | $23.52 | $153,138.72 |
DisclosureSEC source: 0000950138-18-000020 · edgar.xml · nonDerivative · entry 2 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,913 Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 19:08 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 10,046 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000020 · edgar.xml · nonDerivative · entry 1 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,424 F1 · shares: Vesting of performance share award granted on January 2, 2015. Read SEC document |
| November 13, 2017 Filed Nov 14, 2017 21:17 UTC | TE Connectivity plc TEL · Entity 3004 | Tax withholdingCommon Shares | 512 | $93.36 | $47,800.32 |
DisclosureSEC source: 0001225208-17-017303 · doc4.xml · nonDerivative · entry 2 Trudeau Mark · CIK 0001540412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,988 Read SEC document |
| November 13, 2017 Filed Nov 14, 2017 21:17 UTC | TE Connectivity plc TEL · Entity 3004 | GrantCommon Shares | 2,048 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-017303 · doc4.xml · nonDerivative · entry 1 Trudeau Mark · CIK 0001540412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 F1 · price: Grant of shares by the issuer under directors' compensation program and Issuer's stock and incentive plan. Read SEC document |
| November 10, 2017 Filed Nov 13, 2017 16:14 UTC | Keenova Therapeutics plc MNK · Entity 28960 | PurchaseOrdinary Shares | 5,000 | $22.28 | $111,401.50 |
DisclosureSEC source: 0000950138-17-000752 · edgar.xml · nonDerivative · entry 1 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,378 F1 · price: The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $22.21 to $22.32, inclusive. Mr. Trudeau will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range. F2 · balance_after: Includes 325 shares acquired between April 1, 2017 and September 30, 2017 under the Mallinckrodt employee stock purchase plan. Read SEC document |
| June 09, 2017 Filed Jun 12, 2017 16:22 UTC | Keenova Therapeutics plc MNK · Entity 28960 | PurchaseOrdinary Shares | 1,000 | $40.17 | $40,173.50 |
DisclosureSEC source: 0000950138-17-000480 · edgar.xml · nonDerivative · entry 1 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,053 F1 · price: The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $40.13 to $40.205, inclusive. Mr. Trudeau will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range. F2 · balance_after: Includes 373 shares acquired on March 31, 2017 under the Mallinckrodt employee stock purchase plan. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 08:49 UTC | Keenova Therapeutics plc MNK · Entity 28960 | PurchaseOrdinary Shares | 1,000 | $50.47 | $50,466.40 |
DisclosureSEC source: 0000950138-17-000174 · edgar.xml · nonDerivative · entry 1 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,680 F1 · price: The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $50.45 to $50.49, inclusive. Mr. Trudeau will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range. F2 · balance_after: Includes 128 shares acquired on December 31, 2016 under the Mallinckrodt employee stock purchase plan. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 18:09 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 3,339 | $53.19 | $177,601.41 |
DisclosureSEC source: 0000950138-17-000049 · edgar.xml · nonDerivative · entry 1 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,552 Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:00 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantEmployee Share Options (Right to Buy) · Derivative | 249,785 | $0.00 Strike: $51.73 | $0.00 |
DisclosureSEC source: 0000950138-17-000017 · edgar.xml · derivative · entry 5 Trudeau Mark · CIK 0001540412 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,785 Underlying: Ordinary Shares · 249,785 shares Expires 2027-01-03 F4 · derivative.exercise_date: The options vest in four equal annual installments beginning January 3, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.